Vanda grants Biotoscana exclusive commercialization rights to schizophrenia drug Fanapt in Argentina

Vanda Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$189.7m on 08/05/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Biotoscana S.A.

Colombia / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced